{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:26:49Z","timestamp":1783524409369,"version":"3.55.0"},"reference-count":42,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic liver disease (CLD) encompasses a spectrum of progressive disorders, including metabolic dysfunction steatotic-associated liver disease (MASLD) and primary biliary cholangitis (PBC), which together represent a significant global health burden with few effective therapeutic options. The fibrogenic process, common to most forms of CLD, is driven by a complex interplay of cellular stress, inflammation, and wound-healing responses. Nicotinamide adenine dinucleotide phosphate oxidase isoforms 1 and 4 (NOX1 and NOX4) have emerged as key enzymatic sources of reactive oxygen species (ROS), serving as central mediators of hepatic oxidative stress, fibrogenesis, and inflammation. Setanaxib is a first-in-class, orally bioavailable, selective dual inhibitor of NOX1 and NOX4 that has progressed to clinical evaluation. This review synthesizes current knowledge on the molecular pharmacology of the NOX1\/4 axis, preclinical evidence from translational models, and clinical trial outcomes to critically assess the therapeutic potential of targeted NOX inhibition in hepatic fibrosis. By attenuating hepatic stellate cell activation, modulating TGF-\u03b2 signaling, reducing extracellular matrix (ECM) deposition, and regulating hepatic macrophage polarization, setanaxib exhibits pleiotropic antifibrotic effects. The compound also demonstrates favorable pharmacokinetic properties and a good safety profile in patients with PBC, with emerging evidence suggesting meaningful improvements in fatigue and quality of life. Finally, we examine the complex, and sometimes paradoxical, roles of NOX4 in liver pathophysiology, compare the evolving therapeutic landscape with other approaches such as farnesoid X receptor (FXR) agonists, and propose future paradigms integrating artificial intelligence\u2013driven predictive modeling to optimize patient stratification and therapeutic response in this new era of redox-targeted hepatoprotective therapy.<\/jats:p>","DOI":"10.3390\/ijms27010158","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:05:22Z","timestamp":1766498722000},"page":"158","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Redox Modulation in Hepatic Fibrosis: Translating NOX1\/4 Inhibition to Therapy"],"prefix":"10.3390","volume":"27","author":[{"given":"Ghaith K.","family":"Mansour","sequence":"first","affiliation":[{"name":"College of Pharmacy, Alfaisal University, Riyadh P.O. Box 50927, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0024-3751","authenticated-orcid":false,"given":"Ahmad W.","family":"Hajjar","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh P.O. Box 50927, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Marafini","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Azienda Ospedaliera Policlinico Tor Vergata, 00133 Rome, Italy"},{"name":"Department of Systems Medicine, University of \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-9076","authenticated-orcid":false,"given":"Giovanni","family":"Monteleone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Azienda Ospedaliera Policlinico Tor Vergata, 00133 Rome, Italy"},{"name":"Department of Systems Medicine, University of \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Decharatanachart, P., Chaiteerakij, R., Tiyarattanachai, T., and Treeprasertsuk, S. (2021). Application of Artificial Intelligence in Chronic Liver Diseases: A Systematic Review and Meta-Analysis. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-020-01585-5"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cbi.2011.07.001","article-title":"Molecular Pathogenesis of Hepatic Fibrosis and Current Therapeutic Approaches","volume":"193","author":"Mormone","year":"2011","journal-title":"Chem. Biol. Interact."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Vermot, A., Petit-H\u00e4rtlein, I., Smith, S.M.E., and Fieschi, F. (2021). NADPH Oxidases (NOX): An Overview from Discovery, Molecular Mechanisms to Physiology and Pathology. Antioxidants, 10.","DOI":"10.3390\/antiox10060890"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.freeradbiomed.2009.07.023","article-title":"Nox Proteins in Signal Transduction","volume":"47","author":"Brown","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"742931","DOI":"10.1155\/2014\/742931","article-title":"NADPH Oxidases in Chronic Liver Diseases","volume":"2014","author":"Jiang","year":"2014","journal-title":"Adv. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lan, T., Kisseleva, T., and Brenner, D.A. (2015). Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129743"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/hep.25938","article-title":"Nicotinamide Adenine Dinucleotide Phosphate Oxidase in Experimental Liver Fibrosis: GKT137831 as a Novel Potential Therapeutic Agent","volume":"56","author":"Aoyama","year":"2012","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.freeradbiomed.2008.08.013","article-title":"Distinct Roles of Nox1 and Nox4 in Basal and Angiotensin II-Stimulated Superoxide and Hydrogen Peroxide Production","volume":"45","author":"Dikalov","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1021\/bi500331y","article-title":"Nox4: A Hydrogen Peroxide-Generating Oxygen Sensor","volume":"53","author":"Nisimoto","year":"2014","journal-title":"Biochemistry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"F155","DOI":"10.1152\/ajprenal.00438.2013","article-title":"Upregulation of Mitochondrial Nox4 Mediates TGF-\u03b2-Induced Apoptosis in Cultured Mouse Podocytes","volume":"306","author":"Das","year":"2014","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1165\/rcmb.2013-0174OC","article-title":"An Inhibitor of NADPH Oxidase-4 Attenuates Established Pulmonary Fibrosis in a Rodent Disease Model","volume":"50","author":"Jarman","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zheng, H., Xu, N., Zhang, Z., Wang, F., Xiao, J., and Ji, X. (2022). Setanaxib (GKT137831) Ameliorates Doxorubicin-Induced Cardiotoxicity by Inhibiting the NOX1\/NOX4\/Reactive Oxygen Species\/MAPK Pathway. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.823975"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Sancho, P., Mainez, J., Crosas-Molist, E., Roncero, C., Fern\u00e1ndez-Rodriguez, C.M., Pinedo, F., Huber, H., Eferl, R., Mikulits, W., and Fabregat, I. (2012). NADPH Oxidase NOX4 Mediates Stellate Cell Activation and Hepatocyte Cell Death during Liver Fibrosis Development. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0045285"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"RP95285","DOI":"10.7554\/eLife.95285.4","article-title":"LPS-Induced Systemic Inflammation Is Suppressed by the PDZ Motif Peptide of ZO-1 via Regulation of Macrophage M1\/M2 Polarization","volume":"13","author":"Lee","year":"2024","journal-title":"eLife"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3264858","DOI":"10.1155\/2019\/3264858","article-title":"The NADPH Oxidase Nox4 Controls Macrophage Polarization in an NF\u03baB-Dependent Manner","volume":"2019","author":"Helfinger","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22358","DOI":"10.1038\/s41598-024-72721-4","article-title":"NADPH Oxidase 4 Deficiency Promotes Hepatocellular Carcinoma Arising from Hepatic Fibrosis by Inducing M2-Macrophages in the Tumor Microenvironment","volume":"14","author":"Kim","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.freeradbiomed.2012.05.007","article-title":"Liver Fibrosis and Hepatocyte Apoptosis Are Attenuated by GKT137831, a Novel NOX4\/NOX1 Inhibitor in Vivo","volume":"53","author":"Jiang","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101841","DOI":"10.1016\/j.redox.2020.101841","article-title":"NADPH Oxidase 4 (Nox4) Deletion Accelerates Liver Regeneration in Mice","volume":"40","author":"Gut","year":"2021","journal-title":"Redox Biol."},{"key":"ref_19","unstructured":"(2025, December 08). Study Details|NCT05014672|A Trial of Setanaxib in Patients with Primary Biliary Cholangitis (PBC) and Liver Stiffness|ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05014672."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e0057","DOI":"10.1097\/HC9.0000000000000057","article-title":"Impact of Setanaxib on Quality of Life Outcomes in Primary Biliary Cholangitis in a Phase 2 Randomized Controlled Trial","volume":"7","author":"Jones","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/liv.15596","article-title":"Setanaxib, a First-in-Class Selective NADPH Oxidase 1\/4 Inhibitor for Primary Biliary Cholangitis: A Randomized, Placebo-Controlled, Phase 2 Trial","volume":"43","author":"Invernizzi","year":"2023","journal-title":"Liver Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00535-020-01664-0","article-title":"Emerging Therapies for PBC","volume":"55","author":"Chascsa","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14656566.2025.2516622","article-title":"Advancing Care in Primary Biliary Cholangitis: Emerging Insights and Novel Therapies","volume":"26","author":"Kremer","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_24","unstructured":"Carstens, E., and Akiyama, T. (2014). Pruritus of Cholestasis. Itch: Mechanisms and Treatment, CRC Press\/Taylor & Francis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/jcmm.17649","article-title":"Pre-Clinical Evidence of a Dual NADPH Oxidase 1\/4 Inhibitor (Setanaxib) in Liver, Kidney and Lung Fibrosis","volume":"27","author":"Thannickal","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41392-025-02347-z","article-title":"NADPH Oxidase 1\/4 Dual Inhibition Impairs Transform-ing Growth Factor-Beta Protumorigenic Effects in Cholangiocarcinoma Cancer-Associated Fibroblasts","volume":"10","author":"Amengual","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41419-024-06753-z","article-title":"Autophagy Caused by Oxidative Stress Promotes TGF-\u03b21-Induced Epithelial-to-Mesenchymal Transition in Human Peritone-al Mesothelial Cells","volume":"15","author":"Oh","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.redox.2019.101116","article-title":"Tumoral NOX4 Recruits M2 Tu-mor-Associated Macrophages via ROS\/PI3K Signaling-Dependent Various Cytokine Production to Promote NSCLC Growth","volume":"22","author":"Zhang","year":"2019","journal-title":"Redox Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.cardiores.2005.08.009","article-title":"Matrix Metalloproteinase-2 and -9 Are Induced Differently by Doxorubicin in H9c2 Cells: The Role of MAP Kinases and NAD(P)H Oxidase","volume":"69","author":"Spallarossa","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fiorucci, S., Urbani, G., Distrutti, E., and Biagioli, M. (2025). Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders. Pharmaceuticals, 18.","DOI":"10.3390\/ph18091424"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Anderson, K.M., and Gayer, C.P. (2021). The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity. Cells, 10.","DOI":"10.3390\/cells10113206"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3350\/cmh.2023.0356","article-title":"Recent Updates on Pharmacologic Therapy in Non-Alcoholic Fatty Liver Disease","volume":"30","author":"Chang","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14656566.2024.2374463","article-title":"Pharmacotherapeutic Options for Metabolic Dysfunction-Associated Steatotic Liver Disease: Where Are We Today?","volume":"25","author":"Puengel","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1817-P","DOI":"10.2337\/db20-1817-P","article-title":"1817-P: Elafibranor and Glucagon-Like Peptide-1 Receptor Agonists Synergize to Attenuate Hepatic Inflammation and Fibrosis in a Rodent Model of Obesity, Insulin Resistance, and NASH","volume":"69","author":"Legry","year":"2020","journal-title":"Diabetes"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.14218\/JCTH.2014.00035","article-title":"Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development","volume":"3","author":"Delire","year":"2015","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.freeradbiomed.2014.01.040","article-title":"The NADPH Oxidase NOX4 Inhibits Hepatocyte Proliferation and Liver Cancer Progression","volume":"69","author":"Bertran","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100443","DOI":"10.1016\/j.jhepr.2022.100443","article-title":"Artificial Intelligence in Liver Diseases: Improving Diagnostics, Prognostics and Response Prediction","volume":"4","author":"Nam","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Baciu, C., Xu, C., Alim, M., Prayitno, K., and Bhat, M. (2022). Artificial Intelligence Applied to Omics Data in Liver Diseases: Enhancing Clinical Predictions. Front. Artif. Intell., 5.","DOI":"10.3389\/frai.2022.1050439"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8589","DOI":"10.1038\/s41598-024-59183-4","article-title":"An Explainable Machine Learning Model for Prediction of High-Risk Nonalcoholic Steatohepatitis","volume":"14","author":"Njei","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrd3403","article-title":"Combating Oxidative Stress in Vascular Disease: NADPH Oxidases as Therapeutic Targets","volume":"10","author":"Drummond","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/hep.32702","article-title":"The NADPH Oxidase NOX4 Regulates Redox and Metabolic Homeostasis Preventing HCC Progression","volume":"78","author":"Alay","year":"2023","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Labb\u00e9, P., Thorin, E., and Thorin-Trescases, N. (2025). The Dual Role of NOX4 in Cardiovascular Diseases: Driver of Oxidative Stress and Mediator of Adaptive Remodeling. Antioxidants, 14.","DOI":"10.3390\/antiox14091137"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/158\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:06:36Z","timestamp":1766498796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27010158"],"URL":"https:\/\/doi.org\/10.3390\/ijms27010158","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]}}}